Search Results

CUC and Dr. Yuji Okuno Partner to Expand to Musculoskeletal Embolotherapy in the United States

November 12, 2025—CUC Inc., a provider of health care management and operational support services headquartered in Tokyo, Japan, announced it has signed a Memorandum of Understanding (MOU) with Yuji Okuno, MD, to form a strategic partnership for the expansion of chronic pain treatment business in the United States.

Promising Initial Results on Embolization for Tennis Elbow Presented at SIR 2019

March 24, 2019—Patients with lateral epicondylitis (or "tennis elbow") who have failed to improve with conservative treatments may benefit from transcatheter arterial embolization (TAE), according to results presented by Yuji Okuno, MD, PhD, at the Society of Interventional Radiology's (SIR) 2019 Annual Scientific Sessions in Austin, Texas.

Transcatheter Arterial Embolization Studied as a Treatment for Knee Osteoarthritis

July 14, 2014—Transcatheter arterial embolization as a treatment for mild to moderate knee osteoarthritis was feasible, rapidly relieved resistant pain, and restored knee function, according to a study published by Yuji Okuno, MD, et al online ahead of print in Cardiovascular and Interventional Radiology.

CUC America Forms Collaborations With Drs. Okuno and Ahmed to Advance MSK Embolization and Build a Scalable OBL Platform

April 11, 2026—CUC America, a provider of advanced vascular and interventional care, announced strategic collaborations with Yuji Okuno, MD, and Osman Ahmed, MD, to accelerate the adoption of musculoskeletal (MSK) embolization and expand access to innovative, minimally invasive therapies across the United States.

Interim Results Show Reduced Pain and Improved Function in US Study of Geniculate Artery Embolization for Knee Osteoarthritis

March 20, 2018—Early findings from the first United States–based study exploring geniculate artery embolization (GAE) for knee osteoarthritis (OA) indicate the potential for reductions in pain and stiffness, as well as improved function.

NextBioMedical Begins Pivotal RESORB Trial of Nexsphere-F Microsphere for Genicular Artery Embolization

October 13, 2025—NextBioMedical Co., Ltd., a South Korea–based developer of embolic materials for interventional pain and vascular therapy, announced that the first patient in the United States was enrolled in the company’s RESORB pivotal clinical trial of its Nexsphere-F microsphere, a device for musculoskeletal pain embolization.